Heron Therapeutics (FRA:AXD2) Valuation Rank


FRA:AXD2 Heron Therapeutics Inc FRA:AXD2
49 GF Score
Price €0.35
GF Value €1.28
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Heron Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Heron Therapeutics Valuation Rank Related Terms

FRA:AXD2
49GF Score
Heron Therapeutics Inc FRA:AXD2
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Heron Therapeutics (FRA:AXD2) Overvalued in 2026?

Based on GuruFocus' analysis, Heron Therapeutics stock appears to be undervalued. The current stock price of €0.35 is trading 72.4% below its estimated GF Value™ of €1.28. GuruFocus considers Heron Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:AXD2:

  • Valuation Rank:
  • GF Value™: €1.28 vs. price of €0.35 (72.4% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the FRA:AXD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heron Therapeutics Business Description

Other Exchanges HRTX:USA0J4V:UKAXD2:Germany
Address 100 Regency Forect Drive, Suite 300, Cary, NC, USA, 27518
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
49GF Score

Get the complete analysis for FRA:AXD2

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.35
Price
€1.28
GF Value